Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.

Nature - 1 Jan 2023

Iketani Sho, Mohri Hiroshi, Culbertson Bruce, Hong Seo Jung, Duan Yinkai, Luck Maria I, Annavajhala Medini K, Guo Yicheng, Sheng Zizhang, Uhlemann Anne-Catrin, Goff Stephen P, Sabo Yosef, Yang Haitao, Chavez Alejandro, Ho David D

Abstract excerpt

Nirmatrelvir, an oral antiviral targeting the 3CL protease of SARS-CoV-2, has been demonstrated to be clinically useful against COVID-19 (refs. 1,2). However, because SARS-CoV-2 has evolved to become resistant to other therapeutic modalities3-9, there is a concern that the same could occur for nirmatrelvir. Here we examined this possibility by in vitro passaging of SARS-CoV-2 in nirmatrelvir using two independent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to COVID-19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to COVID-19 Drug Treatment

Share to CRISPR and Genetic Engineering

Share to Drug Resistance, Viral

Share to Mutation

Share to SARS-CoV-2

Share to SARS-CoV-2 and COVID-19 Research

Source

Open in PubMed Open full text

Identifiers

PMID: 36351451
DOI: 10.1038/s41586-022-05514-2
PMCID: PMC9849135

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.PMID 36351451Read ↗

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvirSemantic proximity Read ↗

Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.Semantic proximity Read ↗

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvirSemantic proximity Read ↗

A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibilitySemantic proximity Read ↗

Cross-resistance patterns in SARS-CoV-2 against 3CL protease inhibitors.Semantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture systemSemantic proximity Read ↗

Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in VitroSemantic proximity Read ↗

Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main proteaseSemantic proximity Read ↗

SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.Semantic proximity Read ↗

Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitorsSemantic proximity Read ↗

A comprehensive study of SARS-CoV-2 main protease (M <sup>pro</sup> ) inhibitor-resistant mutants selected in a VSV-based systemSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.